GlassScriptPhysician profile
Wonjin Rhi
NPI 1205488277
$4,329.59
in general payments reported to CMS, 2019-2025
30 companies · $671 in 2025
The $671 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $675 · 2022: $1,172 · 2023: $903 · 2024: $910 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.70 | 2022-2025 | |
| Novo Nordisk INC | $458.15 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $433.72 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $405.02 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $367.20 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $344.15 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $270.13 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.45 | 2023 | |
| Astellas Pharma US INC | $149.59 | 2021-2024 | Veozah |
| Gilead Sciences, INC. | $117.89 | 2021-2023 | |
| Dexcom, INC. | $116.61 | 2022-2025 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $105.27 | 2024-2025 | Horizant, Edarbi |
| Radius Health, INC. | $98.55 | 2023-2025 | Tymlos |
| Pfizer INC. | $83.16 | 2023-2024 | |
| Medtronic, INC. | $81.34 | 2023-2024 | Interstim, Intellis Adaptivestim |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $59.73 | 2023 | Prehevbrio |
| Insulet Corporation | $40.59 | 2022-2024 | Omnipod |
| Glaxosmithkline, LLC. | $40.50 | 2024-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $39.40 | 2021 | |
| Vivus LLC | $38.70 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.07 | 2023-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $35.70 | 2021 | |
| Genentech USA, INC. | $32.31 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.15 | 2023 | Evkeeza |
| Scilex Pharmaceuticals INC. | $24.68 | 2023 | Ztlido |
| Sumitomo Pharma America, INC. | $21.36 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $20.09 | 2025 | Opsumit, Uptravi |
| Ethicon US, LLC | $15.76 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.89 | 2021 | |
| Exact Sciences Corporation | $13.73 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonjin Rhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.